Veritas Pharma Stock Performance
| VRTHF Stock | USD 0 0.00 0.00% |
The entity has a beta of 0.0, which indicates not very significant fluctuations relative to the market. the returns on MARKET and Veritas Pharma are completely uncorrelated.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Veritas Pharma has generated negative risk-adjusted returns adding no value to investors with long positions. Despite nearly stable technical indicators, Veritas Pharma is not utilizing all of its potentials. The latest stock price disturbance, may contribute to mid-run losses for the stockholders. ...more
| Begin Period Cash Flow | 481.00 | |
| Total Cashflows From Investing Activities | 386.00 |
Veritas |
Veritas Pharma Relative Risk vs. Return Landscape
If you would invest 0.15 in Veritas Pharma on August 28, 2024 and sell it today you would earn a total of 0.00 from holding Veritas Pharma or generate 0.0% return on investment over 90 days. Veritas Pharma is currently producing negative expected returns and takes up 0.0% volatility of returns over 90 trading days. Put another way, 0% of traded pink sheets are less volatile than Veritas, and 99% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Veritas Pharma Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Veritas Pharma's investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Veritas Pharma, and traders can use it to determine the average amount a Veritas Pharma's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| VRTHF |
Based on monthly moving average Veritas Pharma is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Veritas Pharma by adding Veritas Pharma to a well-diversified portfolio.
Veritas Pharma Fundamentals Growth
Veritas Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Veritas Pharma, and Veritas Pharma fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Veritas Pink Sheet performance.
| Return On Equity | -5.67 | |||
| Return On Asset | -0.21 | |||
| Current Valuation | 1.77 M | |||
| Shares Outstanding | 71.14 M | |||
| Price To Earning | 0.20 X | |||
| Price To Book | 0.43 X | |||
| EBITDA | (491.67 K) | |||
| Cash And Equivalents | 125.27 K | |||
| Total Debt | 765.63 K | |||
| Debt To Equity | 0.05 % | |||
| Book Value Per Share | (0.04) X | |||
| Cash Flow From Operations | (294.86 K) | |||
| Earnings Per Share | (0.03) X | |||
| Total Asset | 730 | |||
About Veritas Pharma Performance
By analyzing Veritas Pharma's fundamental ratios, stakeholders can gain valuable insights into Veritas Pharma's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Veritas Pharma has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Veritas Pharma has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Indigenous Bloom Hemp Corp. focuses on the production of hemp products for commercial use. It sells hemp biomass and flowers, as well as phytocannabinoid rich extracts derived from hemp biomass. Indigenous Bloom is traded on OTC Exchange in the United States.Things to note about Veritas Pharma performance evaluation
Checking the ongoing alerts about Veritas Pharma for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Veritas Pharma help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Veritas Pharma generated a negative expected return over the last 90 days | |
| Veritas Pharma has some characteristics of a very speculative penny stock | |
| Veritas Pharma has high likelihood to experience some financial distress in the next 2 years | |
| Veritas Pharma has accumulated 765.63 K in total debt with debt to equity ratio (D/E) of 0.05, which may suggest the company is not taking enough advantage from borrowing. Veritas Pharma has a current ratio of 0.63, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist Veritas Pharma until it has trouble settling it off, either with new capital or with free cash flow. So, Veritas Pharma's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Veritas Pharma sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Veritas to invest in growth at high rates of return. When we think about Veritas Pharma's use of debt, we should always consider it together with cash and equity. | |
| Net Loss for the year was (2.29 M) with loss before overhead, payroll, taxes, and interest of (112.96 K). | |
| Veritas Pharma has accumulated about 125.27 K in cash with (294.86 K) of positive cash flow from operations. | |
| Roughly 27.0% of Veritas Pharma outstanding shares are owned by insiders |
- Analyzing Veritas Pharma's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Veritas Pharma's stock is overvalued or undervalued compared to its peers.
- Examining Veritas Pharma's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Veritas Pharma's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Veritas Pharma's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Veritas Pharma's pink sheet. These opinions can provide insight into Veritas Pharma's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Veritas Pink Sheet analysis
When running Veritas Pharma's price analysis, check to measure Veritas Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Veritas Pharma is operating at the current time. Most of Veritas Pharma's value examination focuses on studying past and present price action to predict the probability of Veritas Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Veritas Pharma's price. Additionally, you may evaluate how the addition of Veritas Pharma to your portfolios can decrease your overall portfolio volatility.
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope |